Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel diseaseJ Schultheiss, Bas Oldenburg, Remi Mahmoud et al.|Alimentary Pharmacology & Therapeutics|2021Cited by 49
Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle ContainerJ Schultheiss, Herma H. Fidder, Sandra Altena et al.|Digestive Diseases and Sciences|2020Cited by 10
P414 Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel DiseaseRemi Mahmoud, Bas Oldenburg, J Louwers et al.|Journal of Crohn s and Colitis|2021Cited by 3
721: IMMUNOMODULATOR WITHDRAWAL FROM ANTI-TNF THERAPY IS NOT ASSOCIATED WITH LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASERemi Mahmoud, Bas Oldenburg, J Schultheiss et al.|Gastroenterology|2022Cited by 0
DOP75 Loss-of-response and immunogenicity following immunomodulator withdrawal from anti-tumour necrosis factor alpha combination therapy: Results from a large retrospective cohort studyRemi Mahmoud, Bas Oldenburg, J Schultheiss et al.|Journal of Crohn s and Colitis|2021Cited by 0